Literatura - klinické studie
Xenical a DM2
1) Miles J, Leiter L, Aronne LJ, Wadden T, Anderson J, Doyle M, et al.Effect of orlistat in overweight or obese patients with type 2 diabetestreated with metformin. Diabetes Care. 2002; 25: 1123-8.
http://care.diabetesjournals.org/
2) Kelley D, Bray GA, Pi-Sunyer X, Klein S, Hill JO, Miles J, et al. Clinicalefficacy of orlistat therapy in overweight and obese patients with insulin-treatedtype 2 diabetes mellitus: a one-year, randomized, controlled trial.Diabetes Care. 2002; 25: 1033-41.
http://care.diabetesjournals.org/
3) Kelley D, Jneidi M. Orlistat in the treatment of type 2 diabetes mellitus.Expert Opin Pharma. 2002; 3: 599-606.
http://www.ncbi.nlm.nih.gov/
4) Hollander P, Elbein S, Hirsch I, Kelley D, McGill J, Taylor T, et al.Role of orlistat in the treatment of obese patients with type 2 diabetes:A 1-year randomized double-blind study. Diabetes Care. 1998; 21: 1288-94.
http://care.diabetesjournals.org/cgi/reprint/21/8/1288
5) Keating GM, Jarvis B Orlistat in the Prevention and Treatment of Type2 Diabetes Mellitus. Drugs 2001; 61(14): 2107
http://www.ncbi.nlm.nih.gov/
6) Kelley DE, Kuller LH, McKolanis TM, Harper P, Mancino J, Kalhan SEffects of Moderate Weight Loss and Orlistat on Insulin Resistance, RegionalAdiposity, and Fatty Acids in Type 2 Diebetes, Diabetes Care.2004;27:33-40
http://care.diabetesjournals.org/
Xenical a prevence DM2
1) Torgerson JS, Hauptman J, Boldrin MN, Sjöström L XENical in the Preventionof Diabetes in Obese Subjects (XENDOS) Study: A randomized… DiabetesCare.2004;27: 155-161 http://care.diabetesjournals.org/
2) Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, RissanenA, Wilding JP, Sjostrom L. Effects of weight loss with orlistat on glucosetolerance and progression to type 2 diabetes in obese adults. Arch InternMed. 2000 May 8;160(9):1321-6.
http://www.ncbi.nlm.nih.gov/
3) Keating GM, Jarvis B Orlistat in the Prevention and Treatment of Type2 Diabetes Mellitus. Drugs 2001; 61(14): 2107
http://www.ncbi.nlm.nih.gov/
4) Laville M. Is it possible to prevent type 2 diabetes? Ann Endocrinol(Paris). 2003 Jun;64(3 Suppl):S37-44.
http://www.ncbi.nlm.nih.gov/
5) Zimmet, P., Shaw, J. & Alberti, K. G. M. M. (2003)
Preventing Type 2 diabetes and the dysmetabolic syndrome in the real world:a realistic view.
Diabetic Medicine 20 (9), 693-702.
http://www.blackwell-synergy.com/
Xenical a rizikové faktory aterosklerozy
Tonstad S, Pometta D, Erkelens DW, Ose L, Moccetti T, Schouten JA, etal. The effect of the gastrointestinal lipase inhibitor, orlistat, onserum lipids and lipoproteins in patients with primary hyperlipidemia.Eur J Clin Pharmacol. 1994; 46: 405-10.
http://www.ncbi.nlm.nih.gov/
Bakris G, Calhoun D, Egan B, Hellmann C, Dolker M, Kingma I. Orlistatimproves blood pressure control in obese subjects with treated but inadequatelycontrolled hypertension. J Hypertens. 2002; 20: 2257-67.
http://www.ncbi.nlm.nih.gov/
Broom I, Hughes E, Dodson P, Reckless J. The role of orlistat in the treatmentof obese patients with mild to moderate hypercholesterolaemia: consequencesfor coronary risk. Brit J Cardiol. 2002; 9: 460-8.
http://www.bjcardio.co.uk/
BroomBJC.pdf
Pozn: odkaz nelze nalézt na medline. Do Br.J Cardiol je možno se bezplatněna internetu zaregistrovat
Lucas C, Boldrin M, Reaven G. Effect of orlistat added to diet (30% ofcalories from fat) on plasma lipid, glucose, and insulin in obese patientswith hypercholesterolemia. Am J Cardiol. 2003; 91: 961-4.
www.ncbi.nlm.nih.gov
Reaven G, Segal K, Hauptman J, Boldrin M, Lucas C. Effect of orlistat-assistedweight loss in decreasing coronary heart disease risk in patients withSyndrome X. Am J Cardiol. 2001; 87: 827-31.
http://www.ncbi.nlm.nih.gov/
Tan K, Tso A, Tam S, Pang R, Lam K. Acute effect of orlistat on post-prandiallipaemia and free fatty acids in overweight patients with Type 2 diabetesmellitus. Diabetic Med. 2002; 19: 944-8.
http://www.ncbi.nlm.nih.gov/
Reitsma JB, Cabezas MC, de Bruin TW, Erkelens DW. Relationship betweenimproved postprandial lipemia and low-density lipoprotein metabolism duringtreatment with tetrahydrolipstatin, a pancreatic lipase inhibitor. MetabClin Exp. 1994; 43: 293-8.
http://www.ncbi.nlm.nih.gov/
Tong PC, Lee ZS, Sea MM, Chow CC, Ko GT, Chan WB, et al. The effect oforlistat-induced weight loss, without concomitant hypocaloric diet,on cardiovascular risk factors and insulin sensitivity in young obeseChinese subjects with or without type 2 diabetes. Arch Intern Med. 2002;162: 2428-35.
http://www.ncbi.nlm.nih.gov/
Lindgarde F. The effect of orlistat on body weight and coronary heartdisease risk profile in obese patients: The Swedish Multimorbidity Study.J Intern Med. 2000; 248: 245-54.
http://www.ncbi.nlm.nih.gov/
Muls E, Kolanowski J, Scheen A, Van Gaal L. The effects of orlistat onweight and on serum lipids in obese patients with hypercholesterolemia:a randomized, double-blind, placebo-controlled, multicentre study. IntJ Obes. 2001; 25: 1713-21
http://www.ncbi.nlm.nih.gov/
Zavoral J. Treatment with orlistat reduces cardiovascular risk in obesepatients. J Hypertens. 1998; 16: 2013-7.
http://www.ncbi.nlm.nih.gov/
Sharma AM, Golay A. Effect of orlistat-induced weight loss on blood pressureand heart rate in obese patients with hypertension. J Hypertens. 2002;20: 1873-8.
http://www.ncbi.nlm.nih.gov/
Broom I, Wilding JP, Stott P, Myers N. Randomized trial of the effectof orlistat on body weight and cardiovascular disease risk profile inobese patients: UK Multimorbidity Study. Int J Clin Pract. 2002; 56:494-9.
http://www.ncbi.nlm.nih.gov/
Davidson M, Hauptman J, Digirolamo M, Foreyt J, Halsted C, Heber D, etal. Weight control and risk factor reduction in obese subjects treatedfor 2 years with orlistat. JAMA. 1999; 281: 235-42.
http://www.ncbi.nlm.nih.gov/
Tato stránka je určena pouze pro odbornou veřejnost.